Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) after it failed to improve disease-free survival as an adjuvant therapy in the treatment of patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy.
The decision was made on the recommendation of the Data Monitoring Committee following an interim analysis of the 274-participant trial, which was conducted in partnership with SFJ Pharmaceuticals, on the basis of its “futility”.
Original Article: Pfizer shuts down kidney cancer drug trial due to "futility"